Schroder British Opportunities (SBO)
09/12/2025
Results analysis from Kepler Trust Intelligence
Schroder British Opportunities (SBO) has released its half-year report for the period ending 30/09/2025, which saw NAV per share decrease by 0.6% on a total return basis. The share price rose by 7.9%, leading to the discount to narrow by c. 5 percentage points.
Operational performance from the unlisted portfolio was encouraging, best demonstrated by good sales growth and a high percentage of profitability. Current valuation is 1.5x invested cost. However, the unlisted segment of the portfolio detracted, predominately as a result of valuation reductions due to management prudence.
During the period, one new private investment was announced and completed post period. Since, the trust also announced a further investment which will take the unquoted holdings to 12. At period end, cash was 13.2% of NAV, private companies at 70.5% and public companies at 13.9%.
The proposal to transition to a wholly private portfolio was approved by shareholders in the period. In line with new approach, the managers began the process of selling down the listed portfolio where appropriate. The aim is for this process to be complete by the end of 2026.
The board has brought forward a continuation vote to 2027. This will allow shareholders to vote on the progress of the new strategy and to elect to embark on a process to crystallise their investments, through the orderly realisation of the trust's assets.
Chair Justin Ward maintained a positive outlook, stating "the UK's deep pool of innovative and high-growth companies continues to offer attractive private equity investment opportunities."
Kepler View
We believe these results are another positive step for Schroder British Opportunities (SBO)'s future. After achieving approval from shareholders, the managers have begun the process of divesting the listed equities and reallocating the proceeds to private (unlisted) companies. This has enabled the managers to buy into the UK's deep pool of innovative, high growth companies, with two new holdings either announced or completed to date.
Whilst the discount narrowed, in our view, a sign of approval from shareholders, there is arguably scope for this to go further due to the good returns on unlisted holdings and the solid operational performance in the period. Furthermore, with the managers selling down the listed holdings and raising cash, we think the effective discount on the unlisted portfolio should be even wider, depending on the remaining cash levels.
In addition, we believe the bringing forward of the continuation vote is a sign of good corporate governance, providing shareholders with an earlier opportunity to vote on the trust's future, whilst also giving the managers time to complete the portfolio transition.
CLICK HERE TO READ THE FULL REPORT
Visit Kepler Trust Intelligence for more high quality independent investment trust research.
Important information
This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.
Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.
The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.
The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.
This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.
Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.
PLEASE SEE ALSO OUR TERMS AND CONDITIONS
Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.